Results 241 to 250 of about 213,347 (314)

Emerging therapeutic advances for immune thrombocytopenia: highlights from selected early‑phase and pivotal trials at the 2025 ASH annual meeting. [PDF]

Exp Hematol Oncol
Cao L, Wang Z, Xiang Q.
europepmc   +1 more source

Active Emergency Management of Adult Acute Epiglottitis: An Analysis of 570 Cases

World Journal of Otorhinolaryngology - Head and Neck Surgery, EarlyView.
ABSTRACT Objective Acute epiglottitis, which is primarily caused by bacterial infection, can quickly progress to life‐threatening airway obstruction. The first 24 h after symptom onset is a critical window for management. However, few studies have evaluated the effect of emergency management during this period or have identified the factors that ...
Bo‐Jun Shen, Xu‐Lan Tang, Chun‐Yan Li, Yang‐Jun Liu, Hong‐Liang Yi, Shan‐Kai Yin, Kai‐Ming Su, Su‐Ru Liu   +7 more
wiley   +1 more source

Relapsed Immune Thrombocytopenic Purpura Following COVID-19 Vaccination in a Patient With Autoimmune Cytopenias. [PDF]

J Med Cases
Lahart E, Akbarshahi L, Barbarovich M, Evans E.   +3 more
europepmc   +1 more source

Differences in Risk Factors for Severe Preeclampsia and HELLP Syndrome in Singleton Versus Twin Pregnancies: A Population‐Based Cohort Study

BJOG: An International Journal of Obstetrics &Gynaecology, EarlyView.
ABSTRACT Objective To examine whether the associations between pre‐pregnancy risk factors and severe preeclampsia/eclampsia (SPE) and/or HELLP syndrome differ between singleton and twin pregnancies. Design A population‐based retrospective cohort study. Setting British Columbia (BC), Canada.
Mackenzie Campbell, Johanna Koegl, Jeffrey N. Bone, Sofia Nicolls, Janet Lyons, Chantal Mayer, Kenneth I Lim, Julie Van Schalkwyk, K. S. Joseph, Sarka Lisonkova, the ORQA group, A. Christoffersen‐Deb, S. Derikvand, S. John, L. Richter, M. Rougerie, Y. Sabr, M. Vidler   +17 more
wiley   +1 more source

Thrombocytopenia in Pregnancy: Clinical Challenges, Maternal-Fetal Risks, and Management Strategies. [PDF]

Life (Basel)
Stavros S, Kathopoulis N, Gerede A, Grigoriadis T, Moustakli E, Zikopoulos A, Arkouli N, Machairoudias P, Tzeli M, Anagnostaki I, Sioutis D, Louis K, Potiris A.   +12 more
europepmc   +1 more source

Efficacy and Tolerability of Weekly Bortezomib, Lenalidomide, and Dexamethasone Protocols in Transplant‐Ineligible Newly Diagnosed Myeloma: An Australian Real‐World, Multicenter Study

Asia-Pacific Journal of Clinical Oncology, EarlyView.
RVD with weekly bortezomib dosing in real‐world newly diagnosed transplant‐ineligible myeloma shows comparable efficacy and reduced toxicity compared to twice‐weekly trial protocols. ABSTRACT Background Lenalidomide, bortezomib, and dexamethasone (RVD) remains a standard of care regimen for newly diagnosed multiple myeloma in centers without access to ...
Samantha Kurniawan, Angela Hwang, Nicole Wong Doo, Tracy King, Christian Bryant, Jennifer Zhang, Kristina Whelan, Parisa Fani‐Molky, Giselle Kidson‐Gerber, Annmarie Bosco, Nada Hamad, Gurdeep Parmar, Fiona Kwok, Sam Lai, Silvia Ling, P. Joy Ho, Georgia McCaughan, Adam Bryant   +17 more
wiley   +1 more source

Real-time active surveillance for drug-induced Thrombocytopenia: A prospective interventional study. [PDF]

Explor Res Clin Soc Pharm
Le BH, Nguyen VP, Nguyen THG, Tran TCK, Le HT, Vu TNM, Vu DAM, Tran TH, Doan TTP, Phung TH, Nguyen HD, Nguyen THH, Nguyen TH.   +12 more
europepmc   +1 more source

Long‐Term Efficacy and Safety of Ligelizumab as Re‐Treatment in Patients With Chronic Spontaneous Urticaria

Allergy, EarlyView.
Ligelizumab re‐treatment in CSU patients showed sustained efficacy and tolerability. Over 50% achieved symptom control (UAS7 ≤ 6) by Week 12; benefits maintained through Week 52. No new safety signals observed; aligns with prior PEARL trial outcomes. CSU, chronic spontaneous urticaria; mg, milligram; q4w, every 4 weeks; UAS, urticaria activity score ...
Ana M. Gimenez‐Arnau, Marcus Maurer, Adam Reich, Chia‐Yu Chu, Diana Deleanu, Gordon Sussman, Jorge Sanchez, Knut Brockow, Koremasa Hayama, Michihiro Hide, Mohamed Denguezli, Raisa Meshkova, Roberta F. J. Criado, Sarbjit Saini, Solange Valle, Eva Hua, Pengpeng Wang, Alis Burciu, Isabelle Indermuehle, Vineeth Varanasi, Yolandi Joubert, Thomas Severin, Manmath Patekar   +22 more
wiley   +1 more source

Prevalence, Risk Factors, Characteristics, and Clinical Outcomes of Thrombocytopenia in the Intensive Care Unit: A Prospective Single-Center Cohort Study. [PDF]

Crit Care Res Pract
Almardod ZA, Sam KG, Younis EE.
europepmc   +1 more source

Update on Non‐Biological and RNA‐Based Therapeutics in Chronic Inflammatory Diseases: Precision Medicine Through Small Molecules: An EAACI Position Paper

Allergy, EarlyView.
ABSTRACT In the last decades, critical advancements in research technology and knowledge on disease mechanisms steered therapeutic approaches for chronic inflammatory diseases towards unprecedented target specificity. For allergic and chronic lung diseases, biologic drugs pioneered this goal, acquiring on the way—through the clinical use of monoclonal ...
F. Roth‐Walter, I. M. Adcock, C. Benito‐Villalvilla, R. Bianchini, L. Bjermer, G. Caramori, L. Cari, K. F. Chung, Z. Diamant, I. Eguiluz‐Gracia, E. F. Knol, M. Jesenak, F. Levi‐Schaffer, G. Nocentini, L. O'Mahony, O. Palomares, F. Redegeld, M. Sokolowska, B. Van Esch, M. Zurlo, C. Stellato   +20 more
wiley   +1 more source